Biogen, bleeding cash, hints at more cost-cutting under new CEO
Biogen Inc. may see new drug approvals this year - but first, new CEO Christopher Viehbacher is looking at ways to cut costs.
Biogen Inc. may see new drug approvals this year - but first, new CEO Christopher Viehbacher is looking at ways to cut costs.